RESEARCH TRIANGLE PARK, N.C. / Feb 26, 2024 / Business Wire / IQVIA™ (NYSE:IQV), has published its 2023 Environmental, Social and Governance (ESG) Report. The annual report provides a detailed account of the organization’s focus on reducing its environmental impact and commitment to accelerating positive outcomes for public health and patients.
“At IQVIA our mission is to accelerate innovation for a healthier world. Our 87,000 healthcare focused employees integrate AI-powered analytics and healthcare expertise to solve the most complex problems for our life science, regulator and provider customers,” said Ari Bousbib, Chairman and Chief Executive Officer of IQVIA. “We are proud that we delivered on our sustainability commitments despite the tumultuous macro-environment we have been operating in.”
IQVIA’s full 2023 ESG report can be downloaded here. Below are selected highlights:
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 87,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
Last Trade: | US$233.89 |
Daily Change: | 0.91 0.39 |
Daily Volume: | 761,177 |
Market Cap: | US$42.640B |
July 22, 2024 June 12, 2024 May 02, 2024 April 08, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB